Clinical Trial Update: A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study) [Phase 1]

View source ↗

Summary

Phase I study evaluating the safety and immunogenicity of the rgp120/HIV-1IIIB vaccine in healthy adults, with an extension for participants previously enrolled…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• rgp120/HIV-1IIIB vaccine (recombinant gp120 HIV-1IIIB vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED